Amneal Pharmaceuticals, Inc.
AMRX
Hisse Senetlerindeki Sıralama
#2932
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is... Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
Hisse Fiyatı
$19.83
Piyasa Değeri
$6.33B
Değişim (1 gün)
2.43%
Değişim (1 yıl)
93.65%
Ülke
US
Ticaret Amneal Pharmaceuticals, Inc. (AMRX)
Kategori
Healthcare
Amneal Pharmaceuticals, Inc. (AMRX) için gelir
Jun 2026 itibarıyla gelir TTM: $3.12B
Amneal Pharmaceuticals, Inc. şirketinin en son finansal raporlarına göre, mevcut geliri (TTM) $3.12B'dir. 2023 yılında şirketin geliri $2.39B önceki yıla göre artış 2022 yılındaki $2.21B gelirine göre. Gelir, bir şirketin mal veya hizmet satışından elde ettiği toplam tutardır. Kazançtan farklı olarak, hiçbir gider düşülmez.
Amneal Pharmaceuticals, Inc. için 2014 ile 2026 arasındaki gelir geçmişi
Her yılın sonunda gelir
| Yıl | Gelir | Değiştir |
|---|---|---|
| 2026 (TTM) | $3.12B | 11.58% |
| 2024 | $2.79B | 16.73% |
| 2023 | $2.39B | 8.20% |
| 2022 | $2.21B | 5.67% |
| 2021 | $2.09B | 5.08% |
| 2020 | $1.99B | 22.51% |
| 2019 | $1.63B | -2.20% |
| 2018 | $1.66B | 60.88% |
| 2017 | $1.03B | 1.52% |
| 2016 | $1.02B | 17.54% |
| 2015 | $866.28M | 10.27% |
| 2014 | $785.62M | 0.00% |
Benzer şirketler veya rakiplerin geliri
| Şirket | Gelir | Gelir Farkı | Ülke |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 112.08% |
IN
|
